Medicine Fact: Laninamivir, the neuraminidase inhibitor mentioned, is approved for treatment in Japan but is still undergoing clinical trials elsewhere but never picked up steam in other countries as the mainstay of pharmacological treatment is Oseltamivir (aka Tamiflu). Oseltamivir, however, is only recommended in the first 48 hours of symptom onset and is only recommended for the high risk population (eg, pediatric and geriatric). However, there is generally some controversy over its use data has been emerging over inefficacy in criterion such as prevention of hospitalization. Currently, the mainstay of treatment is supportive/symptomatic therapy (aka, give fluids, rest, pain relief).